Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Either Octreotide LAR or Lanreotide Autogel

NCT02396953 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT02396953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02396953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Either Octreotide LAR or Lanreotide Autogel
Lead sponsor
Ipsen
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2015
Completion date
November 28, 2017
Enrollment
28 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly